| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |